IOBT / IO Biotech, Inc. - Net Long/Short Value

IO Biotech, Inc.
US ˙ NasdaqGS ˙ US4497781090

IOBT / IO Biotech, Inc. - Net Long/Short Value
Halaman ini menyediakan penilaian bersih long/short untuk setiap pegangan institusi yang dilaporkan melalui pemfailan 13F atau NPORT. Untuk mengira nilai bersih long/short, kami menambah nilai ekuiti pada nilai opsyen beli dan menolak nilai opsyen jual. Dana yang melaporkan kedudukan pinjaman jual singkat akan melaporkan nilai ekuiti sebagai negatif. Posisi beli bersih akan mempunyai nombor positif dalam lajur bersih long/short, dan posisi singkat jual bersih akan mempunyai nilai negatif dalam lajur tersebut.
Pemilik Nilai Ekuiti
($1000)
Nilai Call
($1000)
Nilai Put
($1000)
Long/Short Bersih
($1000)
GWM Advisors LLC
Acadian Asset Management Llc
Jane Street Group, Llc
Landscape Capital Management, L.l.c.
Geode Capital Management, Llc
PFM Health Sciences, LP
SBI Securities Co., Ltd.
Dauntless Investment Group, LLC
Marshall Wace, Llp
Marex Group plc
Citigroup Inc
Citadel Advisors Llc
Raymond James Financial Inc
BRSIX - BRIDGEWAY FUNDS INC - Ultra-Small Company Market Fund Class N
Sectoral Asset Management Inc
Soleus Capital Management, L.P.
Pivotal bioVenture Partners Investment Advisor LLC
Two Sigma Securities, Llc
XTX Topco Ltd
Morgan Stanley
UBS Group AG
Cubist Systematic Strategies, LLC
Vivo Capital, LLC
Novo Holdings A/S
Bridgeway Capital Management Inc
Bank Of America Corp /de/
Renaissance Technologies Llc
FNCMX - FIDELITY CONCORD STREET TRUST - Fidelity Nasdaq Composite Index Fund
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista